3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Sarcoma
5
Neoplasms
5
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumors
2
Advanced Cancer
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
MSI-H or dMMR Advanced Solid Tumors
1
Lung Neoplasms
1
Leiomyosarcoma
1
Gynecological Cancer
1
Gastrointestinal Stromal Tumors
1
Gastroenteropancreatic Neuroendocrine Tumor G3
1
Fallopian Tube Neoplasms
1
Extensive Small Cell Lung Cancer
1
Esophageal Squamous Cell Carcinoma
1
Digestive System Neoplasms
1
Differentiated Thyroid Cancer
1
Interventions
Paclitaxel
47
Carboplatin
38
liposomal doxorubicin
25
Bevacizumab
23
Gemcitabine
18
Topotecan
15
pembrolizumab
14
mirvetuximab soravtansine
11
rucaparib
8
niraparib
7
Cisplatin
7
1-dodecylpyridoxal
7
trebananib
6
Drug Therapy
6
130-nm albumin-bound paclitaxel
6
Nivolumab
5
Cyclophosphamide
5
cemiplimab
4
sarilumab
3
relacorilant
3
pazopanib
3
oregovomab
3
olaparib
3
Doxorubicin
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
tocilizumab
2
seribantumab
2
phenoxodiol
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Fallopian Tube Neoplasms
×
anlotinib
×
Clear all
NCT02584478
2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3
Unknown
294 enrolled